CAMRF (Camurus AB) Short-Term Debt : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Short-Term Debt?

Camurus AB's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.0 Mil.

Camurus AB Short-Term Debt Historical Data

The historical data trend for Camurus AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Short-Term Debt Chart

Camurus AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Camurus AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Camurus AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Camurus AB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Camurus AB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Camurus AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

CAMX:Sweden CAMXs:UK 0RD1:UK 7CA:Germany

Address

Ideon Science Park, Lund, SWE, SE-223 70

Website

https://www.camurus.com

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.